On May 20, METiS TechBio-P declined 6.73% in regular trading, trading at HKD 18.81 per share, with trading volume of HKD 15.81 million. The stock has been in a sustained pullback since its listing on May 13, when it surged 173% on its debut, with a significant retreat from its first-day high.

On the news front, METiS TechBio, dubbed the world's first AI drug delivery stock, listed on the HKEX on May 13 at an IPO price of HKD 10.50 per share. The company remains in early-stage commercialization, having accumulated approximately RMB 1.5 billion in losses over the past three years with volatile revenue, leaving its growth trajectory yet to be validated. Additionally, certain internationally placed shares carry no lock-up period, creating persistent profit-taking pressure post-listing. As initial new-stock market enthusiasm accelerates its retreat, the share price continues to face downward pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)